Drugs / [18F]fluoroestradiol
[18F]fluoroestradiol
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials · 1 met primary | ||||||
| Phase 2 | NCT05916196 | Apr 2024 → Aug 2027 expected | uterine cancer | Abramson Cancer Center at Penn Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT05960201 | Aug 2023 → Aug 2024 | invasive lobular breast carcinoma | Asan Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04252859 | Dec 2020 → Dec 2024 | invasive lobular breast carcinoma | University of Utah | Terminated | Met primary |
| Phase 2 | NCT04382911 | Aug 2020 → Jul 2022 | endometriosis | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01986569 | Nov 2013 → Nov 2016 | female breast carcinoma | Asan Medical Center | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05486182 | Feb 2022 → Apr 2025 overdue | breast cancer | GE Healthcare | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-fluoroestradiol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04382911 ↗ |
| Known as | 18F-FES | “18F-fluoroestradiol (18F-FES) PET/CT” PMID 40813238 ↗ Oct 2025 |
| Known as | FES | “The primary objective is to evaluate the sensitivity and specificity of 18F-fluoroestradiol (FES) PET/MRI for evaluating endometriosis.” NCT04382911 ↗3“[18F]Fluoroestradiol (FES) PET/CT” NCT04252859 ↗ “[18F]fluoroestradiol (FES)” NCT01986569 ↗ “[18F]fluoroestradiol (FES)” NCT05960201 ↗ |
| Known as | Fluorine-18 (18F) Fluoroestradiol | “Fluorine-18 (18F) Fluoroestradiol” NCT04252859 ↗ |
| Modality | Diagnostic / imaging agent | “PET/CT with 18F-fluoroestradiol (FES) (FDA-approved in 2020) depicts tissues expressing estrogen receptor (ER).” PMID 36919879 ↗ Mar 2023 |
| Route | Intravenous | “after intravenous injection of 111-222 MBq of 18F-FES” PMID 30846327 ↗ Mar 2019 |